Benjamin Hohl - 04 Oct 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Benjamin Hohl
Issuer symbol
ELVN
Transactions as of
04 Oct 2024
Net transactions value
-$287,524
Form type
4
Filing time
08 Oct 2024, 18:56:05 UTC
Previous filing
03 Oct 2024
Next filing
22 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $25,341 +10,218 $2.48 10,218 04 Oct 2024 Direct F1
transaction ELVN Common Stock Sale $281,079 -10,218 -100% $27.51 0 04 Oct 2024 Direct F1, F2
transaction ELVN Common Stock Options Exercise $3,150 +1,270 +174% $2.48 2,000 07 Oct 2024 Direct F1
transaction ELVN Common Stock Sale $34,935 -1,270 -100% $27.51 0 07 Oct 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Options Exercise $0 -10,218 -5.3% $0.000000 182,140 04 Oct 2024 Common Stock 10,218 $2.48 Direct F1, F4
transaction ELVN Stock Option (right to buy) Options Exercise $0 -1,270 -0.7% $0.000000 180,870 07 Oct 2024 Common Stock 1,270 $2.48 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $27.50 to $27.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $27.50 to $27.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.